Search

Your search keyword '"Fry, Edward T.A."' showing total 35 results
Start Over Author "Fry, Edward T.A."
35 results on '"Fry, Edward T.A."'

1. Randomized Trials Fit for the 21st Century: A Joint Opinion From the European Society of Cardiology, American Heart Association, American College of Cardiology, and the World Heart Federation

Author

Bowman, Louise, Weidinger, Franz, Albert, Michelle A., Fry, Edward T.A., Pinto, Fausto J., Achenbach, Stephan, Bowman, Louise, Casadei, Barbara, Collins, Rory, Devereaux, Philip J., Douglas, Pamela S., Frobert, Ole, Goto, Shinya, Grines, Cindy, Harrington, Robert A., Haynes, Richard, Hochman, Judith S., James, Stefan, Kirchhof, Paulus, Komajda, Michel, Lam, Carolyn S.P., Landray, Martin, Maggioni, Aldo, McMurray, John, Medhurst, Nick, Neal, Bruce, Rydén, Lars, Thiele, Holger, Van Gelder, Isabelle, Wallentin, Lars, Yusuf, Salim, and Zannad, Faiez

Published
2023
Full Text
View/download PDF

10. ACC Advocacy

Author

Fry, Edward T.A., primary, Jones, Samuel O., additional, and Morse, Nick, additional

Published
2022
Full Text
View/download PDF

11. Maternal Health

Author

Fry, Edward T.A., primary, Wood, Malissa J., additional, and Walsh, Mary Norine, additional

Published
2022
Full Text
View/download PDF

17. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.

Author

Steinhubl, Steven R., Berger, Peter B., Mann, J. Tift, III, Fry, Edward T.A., DeLago, Augustin, Wilmer, Charles, and Topol, Eric J.

Subjects
Angioplasty, Coronary heart disease -- Drug therapy, Anticoagulants (Medicine) -- Evaluation
Abstract

Patients who will be having angioplasty for coronary artery disease may benefit from taking the anticoagulant drug clopidogrel before the operation. This was the conclusion of a study of 2,116 patients who took the drug 3 to 24 hours before the operation or at the time of the operation. All patients also took aspirin, which also prevents blood clot formation.

Published
2002

18. Safety and efficacy of only 2 weeks of ticlopidine therapy in patients at increased risk of coronary stent thrombosis: results from the Antiplatelet Therapy alone versus Lovenox plus Antiplatelet therapy in patients at increased risk of Stent Thrombosis (ATLAST) trial

Author

Berger, Peter B., Mahaffey, Ken W., Meier, Susan J., Buller, Christopher E., Batchelor, Wayne, Fry, Edward T.A., and Zidar, James P.

Subjects
Ticlopidine -- Evaluation, Thrombosis -- Prevention, Stent (Surgery) -- Complications, Health
Published
2002

25. 2016 ACC/ASE/ASNC/HRS/SCAI Health Policy Statement on Integrating the Healthcare Enterprise

Author

Windle, John R., primary, Katz, Alan S., additional, Dow, J. Paul, additional, Fry, Edward T.A., additional, Keller, Andrew M., additional, Lamp, Terran, additional, Lippitt, Alexander, additional, Paruche, Marianne P., additional, Resnic, Frederic S., additional, Serwer, Gerald A., additional, Slotwiner, David J., additional, Tcheng, James E., additional, Tilkemeier, Peter L., additional, Weiner, Bonnie H., additional, and Weintraub, William S., additional

Published
2016
Full Text
View/download PDF

26. Reliable anticoagulation with enoxaparin in patients undergoing percutaneous coronary intervention: The pharmacokinetics of enoxaparin in PCI (PEPCI) study

Author

Martin, Jack L., primary, Fry, Edward T.A., additional, Sanderink, Ger‐Jan C.M., additional, Atherley, Trevor H., additional, Guimart, Colette M., additional, Chevalier, Paul J., additional, Ozoux, Marie‐Laure, additional, Pensyl, Catherine E., additional, and Bigonzi, Frederique, additional

Published
2004
Full Text
View/download PDF

27. Update on Management of In-stent Restenosis

Author

HERMILLER, JAMES B., primary, FRY, EDWARD T.A., additional, PETERS, THOMAS F., additional, ORR, CHARLES M., additional, TASSEL, JAMES VAN, additional, WALLER, BRUCE F., additional, and PINKERTON, CASS A., additional

Published
1998
Full Text
View/download PDF

32. Comparison of six-month outcome of coronary artery stenting in patients with <65, 65-75, and >75...

Author

Nasser, Tony K. and Fry, Edward T.A.

Subjects
*CORONARY artery surgery, *HEART diseases, *AGE factors in disease
Abstract

Compares the difference in outcomes for older and younger patients undergoing coronary artery stenting. Clinical profile of patients; Parameters of sixth-month outcomes; Includes death, myocardial infarction and target vessel revascularization.

Published
1997
Full Text
View/download PDF

33. Lack of Interference by Heparin With Thrombolysis or Binding of Tissue-Type Plasminogen Activator to Thrombi

Author

Fry, Edward T.A. and Sobel, Burton E.

Abstract

Coronary thrombolysis with t-PA is generally implemented with concomitant administration of heparin. However, results of studies in vitro suggest that heparin competes with fibrin for binding of tissue-type plasminogen activator (t-PA), augments activation of free plasminogen, decreases fibrin specificity, and impairs thrombolysis. To define the biological implications of these observations, we characterized effects of therapeutic concentrations of heparin on the binding of t-PA to thrombi formed in whole blood, effects of heparin on activation of plasminogen by t-PA in plasma, and effects of heparin on thrombolysis induced by t-PA in a clot lysis system designed to simulate conditions in vivo. The amount of t-PA bound to thrombi was not affected by heparin (0, 0.5, 1.0, and 5.0 U/mL). When t-PA activity was selectively and irreversibly inhibited by D- Phe-Pro-Arg-chloromethyl ketone (PPACK) the amount of t-PA-PPACK bound was similarly unaffected by heparin. Thrombolysis measured by 125l-fibrin(ogen) release and by reduction of mass of thrombi were not altered by heparin. Heparin did not affect plasminogen consumption induced by t-PA. Plasma concentrations of a-2-antiplasmin after exposure of blood to t-PA were less depressed with increasing concentrations of heparin. Thus, heparin in therapeutic concentrations does not interfere with binding of t-PA to thrombi, augment activation of free plasminogen, or inhibit thrombolysis. Accordingly, it appears likely that concomitant administration of heparin will not impair thrombolysis with t-PA implemented clinically.

Published
1988
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results